Infection with the human immunodeficiency virus (HIV) is characterized by progressive
depletion of CD4+ lymphocytes cells as a result of chronic immune activation. Next to the …

Oral drug administration remains the preferred approach for treatment of HIV in most
patients. Maraviroc (MVC) is the first in class co-receptor antagonist, which blocks HIV entry …

Purpose of Review HIV treatment simplification is typically indicated for virologically
suppressed patients with no baseline resistance-associated mutations (RAMs) or prior …

Background: Dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG/DRV/c)
is reasonable alternative option for patients with existing resistance and/or intolerance to …

Background and objectives Protease inhibitors such as darunavir are an important
therapeutic option in the anti-human immunodeficiency virus arsenal. Current dosage …

The infection by the human immunodeficiency virus (HIV) is typically treated using a
combination of pharmacological agents targeting different stages of the viral cycle …

The work in this thesis characterised the virological outcomes of HIV-1 patients on second-
line ART switching to boosted-darunavir maintenance monotherapy in sub-Saharan Africa …

Background Protease inhibitors such as darunavir are an important therapeutic option in the
anti-HIV arsenal. Current dosage guidelines recommend using cobicistat-or ritonavir …

Introdução: Apesar dos avanços nos últimos anos com a terapia antirretroviral (TARV), o
cenário da multirresistência ainda constitui um desafio na prática clínica. Darunavir …

Sir, Recently, Seang et al. 1 reported their clinical experience with 600/100mg of
darunavir/ritonavir once daily as monotherapy in patients with suppressed HIV viral load. In …